| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2006.06.053 |
| P698 | PubMed publication ID | 16884836 |
| P2093 | author name string | Alejandro Lepetic | |
| Claudia Salgueira | |||
| Javier Altclas | |||
| Mónica Lombardo | |||
| Zbigniew Janowicz | |||
| Juan Dupont | |||
| Ernesto Antunez | |||
| Kenneth von Eschen | |||
| Mauricio Seigelchifer | |||
| Nathaly Arndtz | |||
| Vicente Vázquez | |||
| P2860 | cites work | A prophylactic hepatitis B vaccine with a novel adjuvant system | Q34189153 |
| Treatment of chronic hepatitis B. | Q34547915 | ||
| Hepatitis B control in Europe by universal vaccination programmes: the situation in 2001. | Q34737086 | ||
| Global control of hepatitis B virus infection. | Q34749752 | ||
| Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. | Q37004542 | ||
| A hepatitis B vaccine formulated with a novel adjuvant system | Q38872315 | ||
| Risks of chronicity following acute hepatitis B virus infection: a review | Q40552593 | ||
| Novel hepatitis B vaccines | Q40827817 | ||
| Hepatitis B e antigen and the risk of hepatocellular carcinoma | Q44068676 | ||
| Vertical Transmission of Hepatitis B Antigen in Taiwan | Q45146867 | ||
| Global programme for control of hepatitis B infection | Q71772495 | ||
| Long term (24 months) follow-up of a hepatitis A and B vaccine, comparing a two and three dose schedule in adolescents aged 12-15 years | Q74267819 | ||
| Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system | Q74486539 | ||
| Universal hepatitis B immunization: infant, and infant plus adolescent immunization | Q77894454 | ||
| The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population | Q78424586 | ||
| Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine | Q79078545 | ||
| P433 | issue | 49-50 | |
| P921 | main subject | hepatitis B | Q6853 |
| Hepatitis B vaccine | Q117749 | ||
| vaccine | Q134808 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 7167-7174 | |
| P577 | publication date | 2006-07-12 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine | |
| P478 | volume | 24 |
| Q33721641 | Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists |
| Q60909641 | Application of built-in adjuvants for epitope-based vaccines |
| Q93168696 | Comparison of adjuvants to optimize influenza neutralizing antibody responses |
| Q28972540 | Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands |
| Q83065612 | Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years |
| Q37780347 | Key concepts in immunology |
| Q38073752 | Modern Subunit Vaccines: Development, Components, and Research Opportunities |
| Q82548145 | Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeableHaemophilus influenzaeandMoraxella catarrhalisfrom the nasopharynx in mice |
| Q24643034 | Pathogen recognition and inflammatory signaling in innate immune defenses |
| Q36944222 | Preparation of recombinant vaccines. |
| Q89388768 | Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines |
| Q37216571 | Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial |
| Q99602523 | Self-adjuvanting cancer vaccines from conjugation-ready lipid A analogues and synthetic long peptides |
| Q38992678 | Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists. |
| Q90405003 | Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series |
| Q34400322 | TLR-based immune adjuvants. |
| Q39432584 | Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses. |
| Q37896347 | Targeting of Toll-like receptors: a decade of progress in combating infectious diseases |
| Q36844715 | The perfect mix: recent progress in adjuvant research |
| Q36811131 | Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists |
| Q35008279 | Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection |
| Q36171745 | Update on toll-like receptor-directed therapies for human disease |
Search more.